UDP-glucuronosyltransferase 1-6 is an enzyme that in humans is encoded by the UGT1A6gene.[5][6][7]
Function
UDP-glucuronosyltransferase 1-6 is a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.
This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenolic and planar compounds. Alternative splicing in the unique 5' end of this gene results in two transcript variants.[7]
This enzyme is also responsible for the inactivation of popular analgesic drugs, such as aspirin and acetaminophen, by glucuronidation. The loss of a functional UGT1A6 gene in certain hypercarnivores, and particularly cats, renders the animals extremely sensitive to the adverse effects of these analgesics.[8]
Tukey RH, Strassburg CP (2000). "Human UDP-glucuronosyltransferases: metabolism, expression, and disease". Annual Review of Pharmacology and Toxicology. 40: 581–616. doi:10.1146/annurev.pharmtox.40.1.581. PMID10836148.
King CD, Rios GR, Green MD, Tephly TR (September 2000). "UDP-glucuronosyltransferases". Current Drug Metabolism. 1 (2): 143–61. doi:10.2174/1389200003339171. PMID11465080.
Bock KW, Köhle C (2006). "UDP-Glucuronosyltransferase 1A6: Structural, Functional, and Regulatory Aspects". Phase II Conjugation Enzymes and Transport Systems. Methods in Enzymology. Vol. 400. pp. 57–75. doi:10.1016/S0076-6879(05)00004-2. ISBN 9780121828059. PMID16399343.
Harding D, Jeremiah SJ, Povey S, Burchell B (January 1990). "Chromosomal mapping of a human phenol UDP-glucuronosyltransferase, GNT1". Annals of Human Genetics. 54 (Pt 1): 17–21. doi:10.1111/j.1469-1809.1990.tb00356.x. PMID2108603. S2CID35661967.
Moghrabi N, Clarke DJ, Boxer M, Burchell B (October 1993). "Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2". Genomics. 18 (1): 171–3. doi:10.1006/geno.1993.1451. PMID8276413.
Aono S, Yamada Y, Keino H, Hanada N, Nakagawa T, Sasaoka Y, Yazawa T, Sato H, Koiwai O (December 1993). "Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II". Biochemical and Biophysical Research Communications. 197 (3): 1239–44. doi:10.1006/bbrc.1993.2610. PMID8280139.
Ciotti M, Marrone A, Potter C, Owens IS (December 1997). "Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications". Pharmacogenetics. 7 (6): 485–95. doi:10.1097/00008571-199712000-00007. PMID9429234.
Münzel PA, Lehmköster T, Brück M, Ritter JK, Bock KW (February 1998). "Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6". Archives of Biochemistry and Biophysics. 350 (1): 72–8. doi:10.1006/abbi.1997.0485. PMID9466822.
Duffy CF, O'Kennedy R (September 1998). "Determination of 7-hydroxycoumarin and its glucuronide and sulphate conjugates in liver slice incubates by capillary zone electrophoresis". Journal of Pharmaceutical and Biomedical Analysis. 17 (8): 1279–84. doi:10.1016/S0731-7085(98)00015-6. PMID9800648.
Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, Popescu NC (June 2001). "Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus". Pharmacogenetics. 11 (4): 357–68. doi:10.1097/00008571-200106000-00011. PMID11434514.
